GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 16, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on October 16, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker executing share purchases
- 001-15170 (other) — Commission File Number
FAQ
What is the total number of GSK plc ordinary shares purchased?
The filing states that a 'number' of ordinary shares were purchased, but does not specify the exact quantity.
What is the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the purchased shares.
On what date did GSK plc announce these share repurchases?
GSK plc announced the transactions on October 16, 2025.
Which entity acted as the broker for these share repurchases?
BNP Paribas SA acted as the broker for the share repurchases.
What is the principal executive office address of GSK plc?
The principal executive office address is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 3,067 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-16 07:49:43
Filing Documents
- a5620d.htm (6-K) — 4565KB
- 0001654954-25-011846.txt ( ) — 4566KB
From the Filing
IN OWN SHARES a5620d   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   15 October 2025 Aggregate number of ordinary shares of  31¼  pence each purchased:   405,500 Lowest price paid per share (GBp):   1,608.00p Highest price paid per share (GBp):   1,633.00p Volume-weighted average price paid per share (GBp): 1,617.97p       The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 3,919,500 ordinary shares.   Following the above purchase, the Company will hold 251,384,344 ordinary shares in treasury and have 4,064,029,485 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,064,029,485. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.19 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:   GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     15 October 2025   Investment firm:         BNP Paribas SA     Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   52,742   1,630.00p   1,608.00p   1,617.68p   CHIX   113,621   1,630.00p   1,608.00p   1,618.04p   XLON   239,137   1,633.00p   1,608.00p   1,618.01p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   203   1633.0   XLON   15-Oct-2025   08:00:04   20251015148110347   182   1633.0   XLON   15-Oct-2025   08:00:04   20251015148110349   181   1630.0   BATE   15-Oct-2025   08:01:04   20251015148111637   47   1630.0